Phase 2 Prostate Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who are able to understand and sign a consent form agreeing to take part in the study.
• People who are willing and able to follow all study requirements.
• People who are 18 years of age or older.
• People whose bone scan shows a specific pattern called a "superscan," meaning cancer has spread widely to the bones and shows up with very high uptake on the scan, with little or no activity visible in the kidneys.
• People whose general health and ability to carry out daily activities falls within an acceptable range on a standard medical scale (ECOG 0–2, meaning fully active to capable of limited self-care).
• People whose blood test results meet minimum levels for red blood cells, platelets, and white blood cells — and these levels must have been reached without a recent blood transfusion (within the past 28 days) or medications to boost blood cell production (within the past 21 days).
• People whose kidney function blood test is within an acceptable range (creatinine no higher than 1.5 times the upper limit of normal).
• People who have a confirmed diagnosis of prostate cancer, verified by a tissue or cell sample.
• People who have had a PSMA PET/CT scan showing at least one area of cancer that is PSMA-positive (meaning it has a specific protein on its surface that the treatment targets).
• People whose testosterone levels are at castrate levels, meaning very low (below 50 ng/dL or 1.7 nmol/L).
• People who have already received at least one type of hormone-based cancer therapy targeting the androgen receptor (a class of treatments commonly used in advanced prostate cancer).

Who may not be able to join:

• People who have received certain radioactive bone-targeting treatments (such as Radium-223, Strontium-89, or similar therapies) within the six months before the trial starts.
• People who have previously received any PSMA-targeted radioligand therapy (a type of treatment that uses a radioactive substance attached to a molecule that targets PSMA).
• People who have had systemic anti-cancer treatments — such as chemotherapy, immunotherapy, or certain antibody therapies — within four weeks before the screening visit.
• People who have a known allergic reaction to the study drug (PLUVICTO) or any of its ingredients.
• People who are currently receiving other chemotherapy, immunotherapy, radioligand therapy, or experimental treatments at the same time as this trial.
• People whose kidneys are not functioning well enough, or whose blood counts for red blood cells, white blood cells, or platelets are below the required minimum levels.
• People who have cancer that has spread to the brain or spinal cord covering, unless it was treated successfully and has been stable for at least six months with no ongoing steroid medication needed.
• People who are experiencing, or are at risk of, pressure on the spinal cord from their cancer.
• People who have another type of cancer that may affect how long they are expected to live or interfere with study tests — though certain previously treated skin cancers or superficial bladder cancers may be exceptions (confirm with trial site).
• People who have had major surgery within 30 days before joining the trial.
• People who have plans to conceive a child or father a child during treatment or within six months after treatment ends.

Important: Always verify eligibility with the trial site directly before applying.